Race Walking Emerges as the Next Big Cardio Trend: Fast Walking for Optimal Fitness
MIAMI, May 20, 2025 /PRNewswire/ -- Regular walking is universally celebrated as a great way to keep moving, but often it doesn't elevate the heart rate sufficiently for serious cardiovascular benefits. Enter Race Walking—an Olympic Track & Field event since 1904—that combines intense cardio benefits of running without the joint-pounding impacts.
"Race Walking provides all the health benefits of running but significantly reduces wear and tear on your joints," says Jeremy Goldstein, founder of Fastwalker.com. "You're achieving rigorous cardio exercise while strengthening your hips and knees, which positions you for excellent long-term health."
Unlike a leisurely stroll, Race Walking involves dynamic, purposeful movements designed to elevate your heart rate rapidly. Utilizing vigorous arm swings, hip rotation for increased stride length, and strong calf pushes to propel forward, Race Walkers engage their entire body in ways most traditional exercises cannot match.
"When done correctly, you're getting a total body workout," adds Goldstein. "The arms, core, hips, and legs are all activated extensively."
While Race Walking's dramatic physical movements might look amusing—famously portrayed in the Chris Paul State Farm commercial—Olympians who achieve a mile pace as swift as 5 minutes and 31 seconds clearly demonstrate that this is no laughing matter. Goldstein emphasizes, "It's a remarkable feat, combining incredible speed with minimal joint impact."
Those hesitant to fully adopt Race Walking's precise techniques and official rules can still incorporate its fundamental concepts into their walking routines for enhanced benefits. Fastwalker.com features instructional videos by renowned Race Walking coach and World Athletics Gold Level Judge Jeff Salvage, helping newcomers learn essential techniques.
Goldstein himself integrated these techniques, successfully completing the marathon segment of a grueling 140.6-mile Ironman event. "Using Race Walking methods, I see my heart rate elevated, and I'm achieving the best fitness levels of my life," Goldstein shares. "Anyone can master these techniques and comfortably achieve an 11-minute mile walking pace, preparing them for virtually any competitive event."
Yet, Goldstein advises cautious progression: "Race Walking is more challenging than it appears, rapidly raising your heart rate. Beginners should first familiarize themselves with the proper form before increasing speed or distance."
Ready to elevate your walking routine? Visit www.fastwalker.com to connect directly with Jeremy Goldstein, who eagerly offers personalized advice to incorporate Race Walking into your fitness journey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
CCTV+: 2025 Taklimakan Rally Concludes After thrilling 13-Day Desert Challenge
BEIJING, June 3, 2025 /PRNewswire/ -- The X Power 2025 Taklimakan Rally wrapped up with roaring success on June 1 in northwest China's Xinjiang. Kicking off on May 20, the grueling 13-day event spanned Aksu, Hetian, and Kashi prefectures. This year's course covered a total of 5,183 kilometers, including 2,200 kilometers of timed special stages across deserts, Gobi plains, and river crossings. A total of 23 motorcycles and 105 vehicles participated, with 233 racers from 12 countries battling extreme heat and complex terrain. Czech rider Martin Michek and China's Liu Yangui claimed overall victories in the motorcycle and car categories, respectively. Michek clinched the motorcycle title with a total time of 28 hours, 31 minutes, and 4 seconds, leading a commanding performance by his team. "This race was extremely tough, but I really enjoyed competing in China," said Michek, who participated in the rally for the first time. Liu secured the car division crown with a time of 27 hours, 8 minutes, and 15 seconds. "Winning the overall title was our only goal, and it's the greatest recognition we could receive," Liu said, expressing gratitude to his team and all support staff. Known as "China's Dakar," the Taklimakan Rally is widely regarded as the country's most challenging cross-country rally. Since its inception in 2005, the event has continued to evolve. This year marked the debut of a New Energy Vehicle (NEV) category, with ten vehicles entering the T2.E class. In this inaugural NEV category, Yao Weiqiang of the Great Wall Tank Hi4 Team took the title, finishing in 37 hours, 30 minutes, and 42 seconds. The closing ceremony featured a spectacular drone performance and fireworks show, bringing celebration and relief after 13 intense days. Racers, mechanics, and support crews finally had a moment to breathe, reflect, and enjoy the joy of victory and achievement.
Korea Herald
2 days ago
- Korea Herald
International Healthcare Week 2025 - Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- International Healthcare Week (IHW) 2025, Southeast Asia's premier healthcare event, will be held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (MITEC), Kuala Lumpur. Organised by Informa Markets, IHW 2025 is set to be a transformative platform that accelerates healthcare innovation, fosters regional collaboration, and drives economic growth throughout the healthcare sector. With over 900 leading local, regional, and international exhibitors showcasing more than 15,000 products and services, and an expected attendance of 21,000 professionals from over 50 countries, IHW 2025 offers unmatched opportunities for networking, knowledge exchange, and business development. One Venue, Five Healthcare Trade Sh ows, One Unmissable Event IHW 2025 integrates five flagship international trade exhibitions under one roof, covering the entire healthcare value chain and enhancing opportunities to learn, collaborate, invest, and showcase innovations across healthcare sectors, noted Rungphech (Rose) Chitanuwat, Regional Portfolio Director – ASEAN at Informa Markets. Each exhibition is complemented by dedicated conferences tailored to the specific needs and developments of their respective industries: "Participants at IHW 2025 will have the unique advantage of exploring multiple healthcare sectors and attending 125 conference sessions tailored to diverse healthcare domains - all within a single venue. This integrated format eliminates the need to travel between separate events, allowing attendees to maximise their time and resources while gaining a comprehensive understanding of the latest market trends, innovative technologies, and cutting-edge solutions," said Rungphech. Malaysia – Leading the Way in Healthcare "Malaysia's robust healthcare market expansion, flourishing medical tourism sector, strategic regional location, supportive government initiatives, and ongoing advancements in healthcare infrastructure collectively establish the country as an ideal host for IHW 2025. This event will further cement Malaysia's status as a premier healthcare hub in ASEAN and serve as a gateway for global healthcare collaboration," highlighted Rungphech. As ASEAN Chair in 2025, Malaysia plays a pivotal role in promoting regional healthcare cooperation, addressing critical challenges such as supply chain resilience, digital health adoption, and sustainable health financing through platforms like the EU-ASEAN Health Summit. Strengthening Regional Healthcare Cooperation IHW 2025 is fully aligned with ASEAN's strategic objectives to bolster healthcare systems, enhance health outcomes, and promote equitable access across member states. The event serves as a vital platform for fostering networking and partnerships essential for advancing cross-border collaboration, policy harmonization, and increased investment in healthcare infrastructure and services. This collaborative environment supports key regional initiatives including digital health integration, combating non-communicable diseases, and pandemic preparedness-priorities underscored by recent public health challenges in Southeast Asia. MATRADE: A Strong and Strategic Partner As a valued partner of International Healthcare Week 2025, the Malaysia External Trade Development Corporation (MATRADE), Malaysia's national trade promotion agency, plays a crucial role in enhancing Malaysia's global visibility and reputation in the healthcare sector. Through promotion and fostering international collaborations, MATRADE actively positions Malaysia as a regional medical hub for Southeast Asia and beyond. YB Dato' Seri Reezal Merican Naina Merican, Chairman of MATRADE, emphasized the significance of IHW 2025, stating, "International Healthcare Week serves as a powerful platform that elevates Malaysia's standing as a regional leader in healthcare and medical services. This leading event not only promotes innovation but also directly contributes to our nation's economic growth by attracting world-class exhibitors, regional and international delegates, and top healthcare experts to Malaysia—fueling trade, knowledge sharing, and industry advancement." Join Us at IHW 2025 Healthcare professionals are invited to register online at to secure their place at this free-to-attend event. Don't miss this exceptional opportunity to contribute to shaping the future of the vibrant and evolving healthcare industry in ASEAN and beyond! About Informa Markets Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. We provide marketplace participants around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, targeted digital services and actionable data solutions. We connect buyers and sellers across more than a dozen global verticals, including Pharmaceuticals, Boating, Food, Fashion, and Infrastructure. As the world's leading market-making company, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
Korea Herald
2 days ago
- Korea Herald
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3 rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization"
